Abstract
P105 Treatment options in patients with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen: A single UK cancer centre's experience using patients within the early access programme and cancer drugs fund
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
